Yesterday, at the 2017 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (AAPS) in San Diego, California, Quotient Clinical unveiled its new identity: Quotient Sciences.
Quotient Sciences has 700 employees and five operating sites across the US and UK. Its Translational Pharmaceutics platform integrates formulation development, GMP manufacturing, and clinical research.
“I’ve been coming to this conference for about the last 12 years, and this is the most exciting moment in that 12 years, when I get to unveil our new business, Quotient Sciences,” Mark Egerton, CEO, Quotient Sciences said at the company’s event.
“It’s been a long journey, it’s been a really exciting journey, and there is a lot more to come,” he said.
Today, this rings true as the company announces its acquisition of the Reading, UK-based contract development and manufacturing organization (CDMO) Pharmaterials.
Founded in 2000, Pharmaterials’ 48,000 square foot facility houses 13 GMP manufacturing suites and includes room for future expansion. The company’s service portfolio includes the characterization and optimization of drug substance physical forms, the development of preclinical and clinical formulations, as well as clinical trial manufacturing and drug product supply.
“Over the past 12 months we’ve really looked to expand and increase our footprint and we’ve done three acquisitions in very short order,” said Egerton.
The company’s renaming – and Pharmaterials acquisition – follows Quotient Clinical’s acquisition of Co-Formulate, QS Pharma, and SeaView Research.
“We’re representing a new class of business,” added Egerton. “We integrate aspects that are typically found in disparate CDMO and CRO companies and we bring those together under one organization.”